June #155 : RIP:IL-2 - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

The King of AIDS Awearness

Maddow About You




The L+ Word

Starting HIV meds

Under New Management

The Word: PK Booster

Smoke Gets In Your Fur

Hot Flashes

RIP:IL-2

Under One Roof

Vital Vitamins

Prison Health Care: Sickening

Home, Sweet [New] Home

It’s All About The Benjamins!




Real Life Survivors

Imperfect Attendance

Shining Light

POZ/NEG

(Un)deniable Evidence

Fill in the Blank




Cruz Control

Editor's Letter-June 2009

Your Feedback-June 2009

GMHC Treatment Issues-June 2009



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

June 2009


RIP:IL-2

by Laura Whitehorn

We’ve been talking about Proleukin (interleukin-2, or IL-2, used to treat melanoma and kidney cancers) for more than 15 years. We had hoped that, by raising people’s CD4 cell counts, the experimental immune-based therapy could supplement antiretroviral meds for HIV. But now IL-2 has been shot down: In studies, positive people did no better with Proleukin plus an HIV combo than with HIV meds alone. Adding Proleukin didn’t protect them from death or opportunistic infections—although it did raise their CD4 counts. The CD4 cells Proleukin produces might be ineffectual, or the drug may cause immune damage that undercuts the increase in cells. Either way, it’s out of the running as a treatment for HIV. 

Search: Proleukin_, melanoma , kidney cancer, CD4 cell count, immune-based therapy


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 1 (of 1 total)    

RZ, Washington, DC, 2009-06-09 11:11:46
I took IL2 93 to 96, until the protease inhibitors came out. I have always thought that it saved my life during that period between the old regimens and the new ones, when several friends died. I did get severe depression right after the first treatment,but after that was medicated, I handled it very well. I had thought they were investigating it's possible use to boost the immune systems of elderly people after they gave up on it for HIV. Somne had very bad reactions to it.I was lucky

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    charliehunter
    San Francisco
    California


    TanyaB
    Delray Beach
    Florida


    cortaza100
    Oakland
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.